Jenscare Scientific Announces Positive Six-Month Results for LuX-Valve Plus in Large Annulus Patients

Reuters

Nov 20, 2025

Jenscare Scientific Announces Positive Six-Month Results for LuX-Valve Plus in Large Annulus Patients

Jenscare Scientific Co. Ltd. has announced the release of six-month clinical follow-up results from the global multi-center TRINITY study, evaluating the LuX-Valve Plus transcatheter tricuspid valve replacement in patients with large annulus and severe tricuspid regurgitation at high surgical risk. The data, along with one-year clinical follow-up results of the Ken-Valve in patients with large annulus, were presented at PCR London Valves 2025. The results highlight the potential advantages of the company's products for treating patients with large annulus, addressing unmet clinical needs in this population.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jenscare Scientific Co. Ltd. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584974176"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584974176\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584974176?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 07:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584974176","market":"us","top_or_hot":-1,"title":"Jenscare Scientific Announces Positive Six-Month Results for LuX-Valve Plus in Large Annulus Patients","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jenscare Scientific Announces Positive Six-Month Results for LuX-Valve Plus in Large Annulus Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jenscare Scientific Co. Ltd. has announced the release of six-month clinical follow-up results from the global multi-center TRINITY study, evaluating the LuX-Valve Plus transcatheter tricuspid valve replacement in patients with large annulus and severe tricuspid regurgitation at high surgical risk. The data, along with one-year clinical follow-up results of the Ken-Valve in patients with large annulus, were presented at PCR London Valves 2025. The results highlight the potential advantages of the company's products for treating patients with large annulus, addressing unmet clinical needs in this population.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jenscare Scientific Co. Ltd. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jenscare Scientific Announces Positive Six-Month Results for LuX-Valve Plus in Large Annulus Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJenscare Scientific Announces Positive Six-Month Results for LuX-Valve Plus in Large Annulus Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-20 07:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Jenscare Scientific Announces Positive Six-Month Results for LuX-Valve Plus in Large Annulus Patients\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Jenscare Scientific Co. Ltd. has announced the release of six-month clinical follow-up results from the global multi-center TRINITY study, evaluating the LuX-Valve Plus transcatheter tricuspid valve replacement in patients with large annulus and severe tricuspid regurgitation at high surgical risk. The data, along with one-year clinical follow-up results of the Ken-Valve in patients with large annulus, were presented at PCR London Valves 2025. The results highlight the potential advantages of the company's products for treating patients with large annulus, addressing unmet clinical needs in this population.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jenscare Scientific Co. Ltd. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL6dqwjV:1","article_id":"2584974176","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584974176","pubTimestamp":1763595130,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Jenscare Scientific Co. Ltd. has announced the release of six-month clinical follow-up results from the global multi-center TRINITY study, evaluating the LuX-Valve Plus transcatheter tricuspid valve replacement in patients with large annulus and severe tricuspid regurgitation at high surgical risk. The data, along with one-year clinical follow-up results of the Ken-Valve in patients with large annulus, were presented at PCR London Valves 2025. The results highlight the potential advantages of the company's products for treating patients with large annulus, addressing unmet clinical needs in this population.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jenscare Scientific Co. Ltd. published the original content used to generate this n","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","09877":"健世科技-B"},"translate_title":"Jenscare Scientific宣布LuX-Valve Plus在大瓣环患者中的六个月积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09877":0.9},"content_text":"Jenscare Scientific Announces Positive Six-Month Results for LuX-Valve Plus in Large Annulus Patients\n    \n\n        Jenscare Scientific Co. Ltd. has announced the release of six-month clinical follow-up results from the global multi-center TRINITY study, evaluating the LuX-Valve Plus transcatheter tricuspid valve replacement in patients with large annulus and severe tricuspid regurgitation at high surgical risk. The data, along with one-year clinical follow-up results of the Ken-Valve in patients with large annulus, were presented at PCR London Valves 2025. The results highlight the potential advantages of the company's products for treating patients with large annulus, addressing unmet clinical needs in this population.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jenscare Scientific Co. Ltd. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}